[{"id":"c6f5a208-0467-486b-ae61-20c6294e2319","acronym":"","url":"https://clinicaltrials.gov/study/NCT05262842","created_at":"2022-03-02T16:52:35.385Z","updated_at":"2024-07-02T16:36:03.625Z","phase":"Phase 1","brief_title":"JS001+IMP4297 in Patients With Advanced Cancer","source_id_and_acronym":"NCT05262842","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" HER-2 • PD-L1 • HRD • CDK4","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PD-L1 • HRD • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Paishuning (senaparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 04/06/2024","primary_completion_date":" 04/06/2024","study_txt":" Completion: 06/06/2024","study_completion_date":" 06/06/2024","last_update_posted":"2022-09-21"},{"id":"80e85293-689b-482e-9fed-56afba34dba2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04822961","created_at":"2023-08-24T10:08:21.435Z","updated_at":"2024-07-02T16:36:19.447Z","phase":"Phase 2","brief_title":"Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment","source_id_and_acronym":"NCT04822961","lead_sponsor":"Impact Therapeutics, Inc.","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Paishuning (senaparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2021-12-16"},{"id":"09906e60-159c-4ad6-829b-0d3240c58539","acronym":"","url":"https://clinicaltrials.gov/study/NCT03508011","created_at":"2021-01-17T17:47:05.963Z","updated_at":"2024-07-02T16:36:32.592Z","phase":"Phase 1","brief_title":"A Study of IMP4297 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03508011","lead_sponsor":"Impact Therapeutics, Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Paishuning (senaparib)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 12/16/2020","primary_completion_date":" 12/16/2020","study_txt":" Completion: 12/16/2020","study_completion_date":" 12/16/2020","last_update_posted":"2021-03-30"},{"id":"eac1daef-8913-4418-af7a-fa7e96dc5d21","acronym":"","url":"https://clinicaltrials.gov/study/NCT03507543","created_at":"2021-01-18T17:16:02.477Z","updated_at":"2024-07-02T16:36:32.611Z","phase":"Phase 1","brief_title":"The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03507543","lead_sponsor":"Impact Therapeutics, Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Paishuning (senaparib)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 02/03/2017","start_date":" 02/03/2017","primary_txt":" Primary completion: 09/24/2020","primary_completion_date":" 09/24/2020","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2021-03-30"},{"id":"834fcd73-bcc0-4ada-82ee-2e52f814ae17","acronym":"SABRINA","url":"https://clinicaltrials.gov/study/NCT04089189","created_at":"2021-01-18T20:00:50.798Z","updated_at":"2024-07-02T16:36:38.227Z","phase":"Phase 2","brief_title":"Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer","source_id_and_acronym":"NCT04089189 - SABRINA","lead_sponsor":"Impact Therapeutics, Inc.","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Paishuning (senaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/11/2019","start_date":" 09/11/2019","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2020-11-24"},{"id":"cd2e3f63-776f-443d-aacd-a709eb0fdf1c","acronym":"FLAMES","url":"https://clinicaltrials.gov/study/NCT04169997","created_at":"2021-01-18T20:20:38.655Z","updated_at":"2024-07-02T16:36:50.110Z","phase":"Phase 3","brief_title":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","source_id_and_acronym":"NCT04169997 - FLAMES","lead_sponsor":"Impact Therapeutics, Inc.","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Paishuning (senaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 393","initiation":"Initiation: 12/24/2019","start_date":" 12/24/2019","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2020-02-12"}]